Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 22, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on August 19, 2005, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 29,586 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on August 22, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held in the GSK Trust in the same capacity as other employees. The notification complies with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares transferred (29,586) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the date of the transaction (August 19, 2005) versus the date of notification to the Company (August 22, 2005).
- Review the status of the GSK Trust as a discretionary trust for current and former employees.
- Note that this filing does not impact reported financial metrics as it relates solely to internal share plan administration.